Home|Journals|Articles by Year|Audio Abstracts

Case Report

EJMCR. 2021; 5(1): 26-30

Full recovery of a patient with COVID-19-induced acute kidney injury

Neama Ahmed Abdelaziz, Sherief Ghozy, Alzhraa Salah Abbas, Abdullah Reda, Amr Ehab El-Qushayri, Sheikh Mohammed Shariful Islam.

Cited by 0 Articles

Background: In this report, we discuss the diagnosis and management of a case of COVID-19-induced acute kidney injury (AKI).
Case Presentation: A 58-year-old male with PCR-based COVID-19 diagnosis (at a specialized hospital, Minia, Egypt) was admitted and received supportive medications along with corticosteroids and hydroxychloroquine. After 2 days, the patient developed tachypnoea and desaturation. Therefore, he was transferred to the intensive care unit with a continuous positive airway pressure. On the third day, he developed oliguria with spiking kidney function tests, metabolic acidosis, and eventually anuria on the 6th day. AKI diagnosis was established, and the patient received daily dialysis sessions for 10 days until discharge together with tocilizumab and methylprednisolone. The patient was discharged after normalization and stabilization of his clinical parameters and a second negative PCR swab with continuous follow-up.
Conclusion: Early monitoring of kidney function tests during the infection might help in preventing further kidney damage.

Key words: Coronavirus, infection; COVID-19, kidney, renal failure

Full-text options

Share this Article

Online Article Submission
• ejmanager.com

ejPort - eJManager.com
Refer & Earn
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.